2014•MD Conference ExpressRequires access

Exploring the Value and Costs of Incretin-Based Therapies

Daniel O. Bittner, Clifford J. Bailey

Abstract

The development of incretin-based therapies over the past decade since the approval of exenatide has opened new possibilities for the treatment of type 2 diabetes mellitus (T2DM). This article discusses the various metabolic activities of endogenous GLP-1 and DPP-4 antagonists, the side effects of incretin-based therapies, and the need for new diabetes treatments.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Exenatide, Incretin, Medicine, Diabetes mellitus, Type 2 Diabetes Mellitus, Intensive care medicine, Type 2 diabetes, Liraglutide